| KCNQ3 — Potassium Voltage-Gated Channel Subfamily Q Member 3 | |
|---|---|
| Symbol | KCNQ3 |
| Full Name | Potassium Voltage-Gated Channel Subfamily Q Member 3 |
| Chromosome | 8q24.22 |
| NCBI Gene | 3786 |
| Ensembl | ENSG00000184160 |
| OMIM | 121201 |
| UniProt | O43525 |
| Diseases | Benign Familial Neonatal Seizures, Epilepsy, Early Infantile Epileptic Encephalopathy |
| Expression | Brain, Substantia Nigra, [Cortex](/brain-regions/cortex), [Hippocampus](/brain-regions/hippocampus) |
| Key Mutations | |
| G310V, R230G, D305G, W344R | |
KCNQ3 (Potassium Voltage-Gated Channel Subfamily Q Member 3, also known as Kv7.3) is a gene located on chromosome 8q24.22 that encodes a voltage-gated potassium channel protein essential for neuronal excitability regulation. The KCNQ3 protein forms heteromeric M-channels (M-currents) with KCNQ2 subunits, which are critical for controlling neuronal resting membrane potential and preventing hyperexcitability [1]. Mutations in KCNQ3 are primarily associated with Benign Familial Neonatal Seizures (BFNS) and various forms of epilepsy, but emerging research suggests potential roles in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [2].
The gene is catalogued as NCBI Gene ID 3786, Ensembl ID ENSG00000184160, OMIM 121201, and UniProt O43525.
The KCNQ3 protein is a core component of the voltage-gated potassium channel subfamily Q, specifically the M-channel (Kv7.2/Kv7.3 channel). M-channels are slowly activating and deactivating potassium channels that regulate neuronal excitability by controlling the resting membrane potential [1:1]. When KCNQ2/3 channels open, they allow potassium efflux, which hyperpolarizes the neuron and makes it less likely to fire action potentials. This function is crucial for:
KCNQ3 is widely expressed throughout the central nervous system with high expression in:
Expression data is available from the Allen Human Brain Atlas.
The KCNQ3 protein contains six transmembrane domains (S1-S6), with the S4 segment serving as the voltage sensor. The pore region is formed between S5 and S6 segments, and the channel assembles as a tetramer. The N-terminus and C-terminus contain domains important for channel trafficking, assembly, and modulation.
KCNQ3 mutations account for approximately 10-15% of BFNS cases, a genetic epilepsy syndrome characterized by seizures that begin in the first week of life and typically resolve by 4-24 months [3]. Most BFNS-causing mutations result in loss-of-function of the M-channel, reducing the M-current by 25-50%. Key BFNS-associated mutations include:
More severe de novo KCNQ3 mutations can cause EIEE, formerly known as Ohtahara syndrome, characterized by severe early-onset seizures and developmental regression [4]. These mutations often cause more severe channel dysfunction than BFNS mutations.
Emerging evidence links KCNQ channel dysfunction to Alzheimer's disease pathogenesis:
KCNQ3 may play a protective role in dopaminergic neurons vulnerable in Parkinson's disease:
Retigabine (ezogabine), a KCNQ2/3 channel opener, has been investigated for neurological conditions:
| Mutation | Location | Effect |
|---|---|---|
| G310V | S4-S5 linker | Reduced open probability |
| R230G | S4 voltage sensor | Altered voltage dependence |
| D305G | S5 domain | Gating defect |
| W344R | S6 domain | Dominant-negative effect |
Jentsch, T.J. (2000). Neuronal KCNQ potassium channels: physiology and role in disease. Nature Reviews Neuroscience, 1(1), 21-30. 2000. ↩︎ ↩︎ ↩︎
Plant, L.D. et al. (2016). A common mechanism for amyloid-beta effects on potassium channel function in Alzheimer's disease. Proceedings of the National Academy of Sciences, 113(31), E4405-E4414. 2016. ↩︎ ↩︎
Schroeder, B.C. et al. (1998). Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 channels in BFNE. Nature, 396(6712), 687-690. 1998. ↩︎
Weckhuysen, S. et al. (2013). KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Annals of Neurology, 73(1), 5-17. 2013. ↩︎
Gunthorpe, M.J. et al. (2012). The evolution of retigabine. Nature Reviews Drug Discovery, 11(2), 141-168. 2012. ↩︎